AU726652B2 - Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders - Google Patents

Description

P/00/011 28/5/91 Regulation 3.2(2)

AUSTRALIA

Patents Act 1990

ORIGINAL

COMPLETE

SPECIFICATION

STANDARD

PATENT

be..

C.

.CC,.

CCC.

CC..

Application Number: Lodged:

CC..

CC a C. tC C C *CC C

CC

CCC.

Invention Title: COMBINATION OF NECROSIS-INDUCING SUBSTANCES

WITH

SUBSTANCES WHICH ARE ACTIVATED BY NECROSES FOR THE SELECTIVE THERAPY OF TUMORS AND INFLAMMATORY

DISORDERS.

The following statement is a full description of this invention, including the best method of performing it known to us

I-

BEHRINGWERKE AKTIENGESELLSCHAFT HOE 94/B 006 Ma 1031 Dr.Lp/Bi/Wr.

Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders The invention relates to a combination of substances (component I) inducing necrosis in tumors or inflamed tissue, with other nontoxic substances ("prodrugs", component II). The enzymes set free by necrotic processes then cleave the nontoxic "prodrug" into the toxic "drug", which leads to massive tumor cell death and/or remission of inflammation.

Only chemotherapy is available today for the treatment of advanced (metastasized) solid tumors. This form of therapy does produce a demonstrable antitumor effect in a number of solid tumors but only with usually severe 9 side effects for the patient. From this unsatisfactory 20 situation the urgent need arises to develop better forms of therapy which have low side effects.

In recent years, several attempts were undertaken, based on specific immunological recognition mechanisms, to introduce novel and efficient therapies into the clinic.

It is a matter here especially of therapy attempts in which toxic principles are to be transported to the tumor tissue by means of antibodies which are selective for the surface structures on tumors. In these clinical attempts, it turned out that macromolecules, such as e.g.

monoclonal antibodies or their recombinant variants, do bind very selectively to the tumor cells in vivo, but only to a very low extent which is usually inadequate fortherapy. These scientific results led to the development of so-called multi-step concepts, in which an enzyme was coupled to a tumor-selective monoclonal antibody (antibody-enzyme conjugate), which is able, after an 2 appropriate prelocalization phase on the tumor (1st step), to cleave a nontoxic low-molecular weight prodrug (2nd step) injected afterwards selectively at the tumor site to give a toxic drug. Preclinically this two-phase concept leads to higher drug concentrations on the tumor than conventional chemotherapy, which is accompanied by improved activity in the human tumor xenograft model in the nude mouse (Senter, P.D. et al., Bioconj, Chem. 4: 3-9, 1993). In addition to the immunogenicity which is to be expected of the antibody-enzyme conjugates used (mouse antibody bound to xenogenic, usually bacterial enzymes), their problems of penetration through the solid tumor and their restriction to certain tumor types, depending on the presence of the tumor-associated antigen recognized, are to be mentioned. From this the need results to develop various antibody-enzyme conjugates of different specificity in order to be able to treat at least the most frequent tumors (gastrointestinal tract, pulmonary, breast, ovarian and prostate carcinomas).

0 0 In the following a pharmaceutical product is now presented which surprisingly does not have the problems of immunogenicity, heterogeneity and lack of tumor penetration pointed out above, but has the advantages of the two-phase concept, the improved drug concentration on the tumor, and accordingly makes possible a universally employable low side effect therapy of solid tumors.

The pharmaceutical product consists of two components, one component which \tumor-selectively induces necroses or is selectively toxic for proliferating endothelium (tumor endothelium or endothelium in inflammatory processes) and a nontoxic prodrug component which is cleaved by enzymes set free during necrotic processes to give a toxic drug. The necrosis-inducing component I can be an inhibitor of the tumor or endothelial cell metabolism or a tumor endotheliumspecific substance. The tumor endothelium-specific or necrosis-inducing component I is administered parenterally, preferably intravenously.

In the case of the tumor endothelium-specific component, it binds selectively to one epitope which is expressed preferentially on proliferating endothelium of the Sblood vessels without having to penetrate the tumor interstitium.

In particular, the invention relates to a pharmaceutical product for use in cytostatic or immunoregulating therapy containing one or more active compounds as component I, wherein component I produces necroses in tumors and in inflammatory disorders, and one or more active compounds as component II, wherein component II is activated by the necroses produced by the action of component I.

After internalization of the component into the proliferating endothelial cells or as a result of activation of cytotoxic host effector mechanisms in the case of noninternalization, the proliferating endothelium is inhibited in its growth or completely destroyed. From this an undersupply of nutrient to numerous tumor cells results, which leads to growth inhibition and to the dying of certain tumor areas.

Comparable effects can also be achieved by tumor metabolism- or endothelial o* oo metabolism-inhibiting substances which can be injected In the necrosis thus S formed, intracellular enzymes, preferably lysosomal glycosidases, are released which cleave the component II then preferably to be injected the nontoxic 0. prodrug, to the toxic drug. The high drug concentrations thus produced in the tumor then lead to massive tumor cell death, to the superior antitumor effect of this new two-component therapy and/or remission of inflammation.

25 As component I of the novel two-component system, various substances described in greater detail in the following can be used: a) monoclonal antibodies (MAb), selectively for proliferating endothelium or its humanized variants having complement-activating and/or the "antibody- 3. dependent cell-mediated cytotoxicity" ADCC-mediating Fc part (mode of action by means of cell destruction) and also noncytolytic variants or fragments (induction of apoptosis); b) immunoconjugates of substances described under bound to toxins or toxic chemicals; c) ligand toxins specific for proliferating 4 endothelium, consisting of a receptor ligand bound to toxins or to toxic chemicals; d) tumor cell- or endothelial cell metabolism-inhibiting substances, which in each case locally destroy at least parts of tumor cell populations.

The monoclonal antibodies described under a) are preferably specific for a proliferation-dependent endothelial antigen, such as e.g. the VEGF receptor (Terman et al., 1991, Oncogene 6, 1677-1683; Ullrich and Schlesinger, 1990, Cell 61, 203-212; Millauer et al., 1993, Cell 72, 835-846; Millauer et al., 1994, Nature 367 (6463) 576- 579; Kaipainen et al., 1993, J. Exp. Med. 178 2077- 2088; Plate et al., 1993, Cancer Res. 53, 5822-5827), the antigens on endothelium described by Clarke and West 15 (Electrophoresis, 12 500-508, 1991), the 30.5 kDa tumor endothelium-specific antigen described by Hagemeier *et al. (Int. J. Cancer 38 481-488, 1986), an apoptosis-mediating antigen occurring on proliferating endothelial cells, such as, for example, the vitronectin S 20 receptor (integrin avB3) (Brooks et al., Science, 264, 569-71, 1994; Brooks et al., Cell 79, 1157-64, 1994), the VEGF/VEGF receptor complex (VEGF/FLK1, VEGF/KDR) (Abraham et al., US 52 19739, Abraham et al., WO 91 02058A, Millauer et al., Cell 72, 835-846, 1993; Terman et al., Oncogene 6, 1677-1683, 1991, Terman et al., Biochem.

Biophys. Res. Comm., 187, 1579-1586, 1992), the fibronectin

CH

2 domain (Carnemolla et al., J. Cell Biol. 108, 1139-1148, 1989, Castellani et al., Int. J. Cancer, 59, 612-618, 1994), endoglin (Fernandez-Ruiz et al., Cytogenet. Cell Genet. 64, 204-207, 1993; Gougos et al., J.

Biol. Chem. 265, 8361-8364, 1990), endosialin (Garin- Chesa and Rettich, USP 5 342 757), the antigens defined in WO 94/10331 by means of MAb and occurring on proliferating endothelia, the EAM-1 sialoglycoprotein antigen (EPA 0583 799A), the FLK-2 protein (WO 94/01576), the CMP-170 antigen (EPA 0 585-963 Al), the E9 antigen (Wang et al., Int. J. Cancer 54, 363-370, 1993, Wang et al., J. Immunol. Methods 171, 55-64, 1994), the novel 5 180 kDa dermal endothelial cell-activation antigen (Westphal et al., J. Invest. Dermatol. 100, 27-34, 1993), the FLt protein (Shibuya et al., Oncogene 5, 519-524, 1990; DeVries et al., Science 255, 989-991, 1992), the PDGF receptor 6 (Plate et al., Laboratory Investigation, 67, 529-534, 1992), the PDGF/PDGF receptor #-complex, the PDEGF/PDEGF receptor complex (Ishikawa et al., Nature 338, 557-562, 1989), the inducible, blood-brain barrier endothelium-specific antigen HT7 (neurothelin, basignin; gp 42, OX 47) (Seulberger et al., Annals of the New York Academy of Sciences, 633, 611-614, 1991; Seulberger et al., Neuroscience Letter 140, 93-97, 1992). Additionally to the MAb defined above, the MAb mentioned by Burrows S' and Thorpe (Pharmac. Ther. 64, 155-174, 1994) can also be 15 used. All MAb mentioned in a) can also be used for the preparation of fusion proteins in combination with procoagulating factors (Denekamp, Cancer Topics 6, 6-8, 1986) or cytokines or chemokines (Mulligan, Science 260, 926-932, 1993). Associated with vector DNA, which codes for proinflammatory, immunoregulatory or proliferationinhibiting proteins, the MAb described under which internalize, can especially be used for the "targeting" and'for the modification of the proliferating endothelium (Nabel et al., Science 249, 1285-1288, 1990). In prin- 25 ciple, an internalization, if not mediated by the antigen recognized itself, can be brought about by the administration of a second antibody having specificity against the first. Instead of classical MAb obtained from hybridomas, antibodies obtained from non-human or human gene banks by means of "display libraries" (Little et al., Biotech Adv. 12, 539-555, 1994) and their derivatives such as e.g. "single chain fragment variable region" (scFvs), "domain antibodies" (dAbs), antigenbinding peptides or peptide mimetics with the above specificities can of course also be used. Antigen-binding peptides are in particular the cyclic peptides mentioned in Brooks et al. 3 loc. cit.) which induce apoptosis by means of binding to the vitronectin receptor.

6 The immunoconjugates described under b) are produced by coupling the specific antibodies or their variants defined under a) with toxins of xenogenic origin (ricin A, diphtheria toxin A, Pseudomonas exotoxin A; Burrows and Thorpe, PNAS 90, 8996-9000, 1993) or human origin (angiogenin, RNAses; Rybak et al., PNAS 89, 3165-3169, 1992). Furthermore, linkage with toxic synthetics or natural substances, such as e.g. alkylating agents, antimetabolites, anthracyclines, Vinca alkaloids, taxol, chalichimycin etc., and radioisotopes, preferably a- or -emitters in complexed form Y-90. DOTA:2- (p-nitrobenzyl)-1,4,7,10-tetracyclododecane- N,N',N",N"',N""-tetraacetic acid; Moi et al., J. Am.

Chem. Society, 110, 6266 (1988) can also be carried out.

15 The ligand toxins described under c) are natural or synthetic ligands which bind to the receptors or antigens defined in a) by means of MAb, preferably variants of the "vascular endothelial growth factor" (VEGF) (Shweiki et al. 1993, J. Clin. Invest. 91, 2235-2243), bound to the toxins and toxic substances described under and VEGF antagonists or agonists.

In the case of the tumor cell- or endothelial cell metabolism-inhibiting substances e.g. 5,6-dimethylxanthenone acetic acid or flavoneacetic acid (Zwi et al., Pathology 26, 161-169, 1994), Zilascorb (5,6-0-benzylidene-d-L-ascorbic acid; Pettersen et al., Brit. J.

Cancer 67, 650-656, 1993) or AGM 1470 (Antoine et al., Cancer Res. 54, 2073-2076, 1994) can be used. Other examples of tumor cell metabolism-inhibiting substances are immunoconjugates or fusion proteins, these constructs being selective for an internalizable tumor-associated antigen, bound to a toxic component, preferably a metabolism-inhibiting enzyme, e.g. Pseudomonas exotoxin (Brinkmann et al., Proc. Natl. Acad. Sci. USA, 88, 8616- 8620, 1991), a toxic synthetic such as cyclophosphamide or toxic natural-substance, e.g. daunomycin.

7 The injection of the respective components I described under a) d) into a patient thus results in selective tissue necrosis either as a result of direct damage to the tumor tissue or indirectly as a result of affecting the proliferating endothelium At the same time as and/or after occurrence of the necrosis, prodrugs which can be cleaved by enzymes which are set free during tumor cell necrosis are injected as component II, for example the prodrugs described in EP-A-0 511 917 Al or EP-A-0 595.133, preferably the

N-(

4 glucuronyl-3-nitrobenzyloxycarbonyl)doxorubicin prodrug (called "prodrug" in the examples) described in Bosslet et al. (Cancer Res. 54, 2151-2159, 1994) in Fig. 3.

a..

In the following, animal-experimental examples are described which confirm the superior pharmacodynamic activity of the novel two-component therapy. These animal models have a high predictiveness for the clinical situation.

Example 1: *a The mouse model set up by Burrows and Thorpe (Proc. Natl.

Acad. Sci., USA, 90, 8996-9000, 1993) was used to confirm the superior pharmacodynamic activity of an anti-tumor endothelial immunotoxin (component I) together with the prodrug (F 826) as the component II.

The mouse model is set up as follows: A mixture of 1.4x10 7 C1300 mouse neuroblastoma cells and 6x10 6 C1300 Muy cells (mouse neuroblastoma line transfected with mouse y-interferon) was injected subcutaneously into the right anterior flank of Balb/c nu/nu mice. Fourteen days later, when the tumors had attained a diameter of 0.8 1.2 cm, the animals were randomized into four groups of 6 animals each. The animals received 8 the immunotoxin on day 15 and the prodrug injected i.v.

on days 17, 20 and 23.

The tumor endothelium immunotoxin injected consists of a monoclonal antibody (MAb M 5/114), which is specific for mouse MHC class II molecules of the haplotype d, bound to the deglycosylated ricin A chain. Normal endothelial cells of BalbC nu/nu mice do not express any MHC class II molecules. The y-interferon released locally in vivo by the C1300 Mu7 tumor cells leads, however, in the tumor to an activation of the endothelial cells located there, combined with a clear expression of MHC class II molecules. By means of this, a quasi-tumor endotheliumspecific antigen is produced (apart from mouse B cells, macrophages and some epithelial cells which constitu- 15 tively express the MHC class II antigens). The injection of the immunotoxin should accordingly lead to a preferential binding to the tumor endothelial cells, followed by endothelium destruction after internalization of the conjugate. The necrosis resulting from the tumor 20 endothelium destruction leads to a release of intracellular enzymes, but especially 6-glucuronidase, which should activate the subsequently administered prodrug in the tumor.

In order to confirm this hypothesis, the experimental animals divided into four groups were treated as described in Table i.

Table 1 Treatment scheme Group Immunotoxin; Ag/mouse Prodrug; mg/mouse 1 4 4 2 4 0 3 0 4 4 0 0 9 The tumor growth was determined by measuring two diameters of the tumor which are perpendicular to one another by means of a slide gauge on each day of the experiment.

The tumor volume was determined with the aid of the formula V 1 ab', a being the largest and b the smallest diameter.

The tumors of experimental group 4 showed progressive.

growth. As a result of treatment three times with prodrug (group 3) or with immunotoxin (group strong tumor growth-inhibitory effects were achieved. All animals of group 1 were treated into a complete regression. This experiment confirms the superior activity of the novel two-component therapy with immunotoxin and prodrug.

Instead of the immunotoxin used here which has specificity for HLA antigens of the mouse (Burrows and Thorpe, PNAS 90, 8996-9000, 1993), the components described under b) and c) can be employed in the patient.

Example 2: The pharmacodynamic superiority of the novel two-component .therapy was confirmed in 2 further .independent experiments. Experimental groups in each case containing 6 nude mice were transplanted with the LoVo colon carcinoma or with the Mx-1 breast carcinoma. After the tumors had achieved a 0 of m 5 mm, Zilascorb (Pettersen et al., 1993, Brit. J. Cancer, 67, 650-656; Borretzen et al., USP 4874 780, 1989) was administered i.v. on days 1-7 and the prodrug F 826 on days 8, 11 and 14. The treatment scheme is described in greater detail in Table 2.

10 Table 2 Treatment scheme MX-1 Zilascorb; mg/mouse Prodrug; mg/mouse Group 1 0.4 4 2 0.4 0 3 0 4 4 0 0 LoVo Group 1 0.8 4 2 0.8 0 10 3 0 4 4 0 0

O

The tumor growth was determined as described in Example 1 and monitored over the course of 30 days after the therapy. The subsequent tumor therapeutic effects were observed: *oo.

The experimental groups 4, which were treated with physiological saline solution, showed progressive growth over the treatment period of 38 days. At a tumor diameter of a 20 mm the animals were sacrificed for ethical reasons. A significant inhibition of tumor growth was to be observed in experimental groups 2 and 3. In more than of the animals of the treatment groups 1 tumor regressions were achieved.

These observations show that the novel two-component therapy with Zilascorb and prodrug F 826, in comparison to monotherapy with one of the components, has superior tumor therapeutic activity. In further preclinical in vivo models, in which human pulmonary, breast, prostate, pancreas and gastric carcinomas were used, it was possible to observe effects comparable to those for the MX-1 11 and the LoVo tumor. Using flavoneacetic acid or 5,6-dimethylxanthenoneacetic acid as the first component, results comparable to those with Zilascorb were obtained.

These preclinical in vivo experiments with high predictiveness for the clinical situation show that the novel two-component therapy with tumor cell- or endothelial cell metabolism-inhibiting substances combined with prodrug can be used in a wide range of human tumors of different origin. In the patient, the reagents described under d) would be injected analogously to the animal experiment as component I, followed by F 826 as component

II.

Example 3: a The pharmacodynamic superiority of the novel two-component therapy was confirmed in a further independent experiment. Experimental groups containing 6 animals each were transplanted with the LoVo colon carcinoma. After the tumors had reached a 0 of 5 mm, the scFv construct (Brinkmann, Proc. Natl. Acad. Sci., USA, 88, 8616-8620, 1991) was administered i.v. altogether 4x at 12 hour intervals in each case. The prodrug was administered i.v. on days 3, 6 and 9.after the beginning of the treatment with the ScFv PE40 construct. The treatment S" scheme is summarized in Table 3.

Table 3 Treatment scheme scFv PE40 /g/mouse Prodrug; mg/mouse Group 1 5 4 2 5 0 3 0 4 4 0 0 The following experimental result was obtained: in 12 comparison to the control group 4, in the prodrug group 3 only a partial tumor regression was observed, in the case of ScFv PE40 group 2 only a slowingdown of the tumor growth. In the combination therapy group 1, 4 of 6 animals showed a complete and 2 a partial regression.

This experiment confirms the superior activity of the two-component therapy as exemplified by an immunotoxin which is directed against a tumorassociated antigen (TAA), in combination with prodrug. For administration to the patient, this experiment means that a two-component therapy with the substances described under combined with the prodrug F 826, should result in superior tumor therapeutic activity.

In summary it may be observed here that the combination therapy with components I described under c) and d) and the component II 15 (prodrug) brings about superior tumor therapeutic effects in comparison to monotherapy with the components I or II.

"Comprises/comprising" when used in this specification is taken to specify the presence of stated features, integers, steps or components but does not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.

*•oo

Claims (12)

1. A pharmaceutical product for use in cytostatic or immunoregulatory therapy containing a component I and component II, wherein said component I comprises one or more active compounds that produce necrosis in tumors and in inflammatory disorders, said necrosis resulting in the release of at least one enzyme, and wherein component II comprises one or more active compounds that are activated by said at least one enzyme released by said necrosis, into a cytotoxic drug.

2. The pharmaceutical product as claimed in claim 1, wherein the component I contains at least one of the compounds selected from the group consisting of a cytolytic or apoptotic monoclonal antibody, an immunoconjugate, a receptor ligand toxin specific for proliferating endothelium, and a tumor cell or endothelial cell metabolism inhibitor substance.

3. The pharmaceutical product as claimed in claim 1, wherein the component I contains at least one monoclonal antibody or one receptor ligand which is selective for proliferating endothelium. 0e 0

4. The pharmaceutical product as claimed in claim 3 wherein the monoclonal antibody or receptor ligand is selective for the VEGF/VEGF receptor complex.

The pharmaceutical product as claimed in claim 1, wherein the component I contains at least one monoclonal antibody or ligands or antagonists against an apoptosis-mediating antigen occurring on proliferating endothelial cells, preferably the a vp3 integrin.

6. The pharmaceutical product as claimed in claim 1, wherein the component I contains at least one cytotoxic immunoconjugate. OFO-C 14

7. The pharmaceutical product as claimed in claim 1, wherein the component I contains at least one ligand toxin.

8. The pharmaceutical product as claimed in claim 1, which contains a tumor cell or endothelial cell metabolism-inhibiting substance.

9. The pharmaceutical product as claimed in claim 1, wherein, as component II, one of the prodrugs described in EP 0 540 859 Al and EP 0 595 133 A2 is used.

The pharmaceutical product as claimed in claim 9 wherein the prodrug is N-( 4 -3-glucuronyl-3-nitrobenzyl-oxycarbonyl) doxorubicin. a

11. The use of one or more active compounds (component I) which produce necroses in tumors and in inflammatory disorders said necrosis resulting in the release of at least one enzyme, with one or more active compounds (component II) which are activated by the said at least one enzyme released by the said necroses produced by the first active compounds, for the production of a medicament for the control of tumors and/or inflammatory disorders. V.9*00

12. A method for the treatment and/or control of tumors or inflammatory disorders which includes administering to a subject in need thereof an effective amount of a pharmaceutical product as claimed in any one of claims 1 to DATED this 13th day of September 2000 HOECHST AKTIENGESELLSCHAFT WATERMARK PATENT TRADEMARK ATTORNEYS 290 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA Case: P2945AU01 KJS/ALJ/BPR